Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.71 |
| ▸ | DNA2 | P51530 | 1/20 | 0.67 |
| ▸ | CASP6 | P55212 | 1/20 | 0.67 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897373 | 0.91 | CLEC4M (0.57) | CLEC4MDNA2CASP6CTDSP1KDM4E | |
| SCHEMBL3245558 | 0.83 | CLEC4M (0.52) | CLEC4MDNA2CASP6CTDSP1KDM4E | |
| SCHEMBL28287784 | 0.82 | CLEC4M (0.82) | CLEC4MKDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6537720 | 0.82 | DNA2 (0.78) | CLEC4MDNA2CASP6CTDSP1KDM4E | |
| SCHEMBL22492440 | 0.81 | CLEC4M (0.80) | CLEC4MKDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1244789 | 0.81 | CLEC4M (0.80) | CLEC4MKDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4334739 | 0.81 | DNA2 (1.00) | DNA2CASP6CTDSP1KDM4ECYP1A2 | |
| SCHEMBL1126279 | 0.80 | CLEC4M (0.78) | CLEC4MKDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21101401 | 0.80 | CLEC4M (0.78) | CLEC4MKDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL16341803 | 0.80 | CLEC4M (0.78) | CLEC4MKDM4ECYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008093940-A1 | QUINOLINE DERIVATIVES AS CASPASE-3 INHIBITOR, PREPARATION PROCESS FOR THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUNGJIN PHARMACEUTICAL CO., LTD. (KR) | 2008-08-07 | — | — | WO | disclosed |
| US-7009053-B2 | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same | Yungjin Pharmaceuticals Co., Ltd. (KR) | 2006-03-07 | — | — | US | disclosed |
| EP-1499593-A4 | QUINOLINE DERIVATIVES AS CASPASE-3 INHIBITOR, PREPARATION FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUNGJIN PHARMACAUTICAL CO LTD (KR) | 2006-02-01 | — | — | EP | disclosed |
| EP-1499593-A1 | QUINOLINE DERIVATIVES AS CASPASE-3 INHIBITOR, PREPARATION FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Yungjin Pharmacautical Co., Ltd. (KR) | 2005-01-26 | — | — | EP | disclosed |
| US-20040260094-A1 | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same | YUNGJIN PHARMACEUTICAL CO., LTD. (KR) | 2004-12-23 | — | — | US | disclosed |
| EP-0876345-B1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003093240-A1 | QUINOLINE DERIVATIVES AS CASPASE-3 INHIBITOR, PREPARATION FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUNGJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-11-13 | — | — | WO | disclosed |
| US-6008230-A | TREATING BONE DISEASES CAUSED BY ABNORMAL BONE METABOLISM IN HUMAN BEING OR ANIMALS AS THE INHIBITORS OF BONE RESORPTION OR THE INHIBITORS OF BONE METASTASIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260094-A1 | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same | CASP1, CASP3, CASP2 | CLEC4M 2773/4885DNA2 2129/4885CASP6 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.